Primary cutaneous follicle centre lymphoma Primary Prevention: Difference between revisions
(Created page with "__NOTOC__ {{Primary cutaneous follicle centre lymphoma}} {{CMG}}; {{AE}} {{AS}}{{Soroush}} ==Overview== There are no established measures for the primary prevention of [disea...") |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There are no established measures for the primary prevention of | There are no established measures for the primary prevention of primary cutaneous follicle centre lymphoma. | ||
OR | OR | ||
There are no available vaccines against | There are no available vaccines against primary cutaneous follicle centre lymphoma. | ||
OR | OR | ||
Effective measures for the primary prevention of | Effective measures for the primary prevention of primary cutaneous follicle centre lymphoma include [measure1], [measure2], and [measure3]. | ||
OR | OR | ||
[Vaccine name] vaccine is recommended for [patient population] to prevent | [Vaccine name] vaccine is recommended for [patient population] to prevent primary cutaneous follicle centre lymphoma. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3]. | ||
==Primary Prevention== | ==Primary Prevention== | ||
There are no established measures for the primary prevention of | There are no established measures for the primary prevention of primary cutaneous follicle centre lymphoma. | ||
OR | OR | ||
There are no available vaccines against | There are no available vaccines against primary cutaneous follicle centre lymphoma. | ||
OR | OR | ||
Effective measures for the primary prevention of | Effective measures for the primary prevention of primary cutaneous follicle centre lymphoma include: | ||
*[Measure1] | *[Measure1] | ||
*[Measure2] | *[Measure2] | ||
Line 34: | Line 34: | ||
OR | OR | ||
[Vaccine name] vaccine is recommended for [patient population] to prevent | [Vaccine name] vaccine is recommended for [patient population] to prevent primary cutaneous follicle centre lymphoma. Other primary prevention strategies include: | ||
*[Strategy 1] | *[Strategy 1] | ||
*[Strategy 2] | *[Strategy 2] |
Latest revision as of 16:01, 29 October 2019
Primary cutaneous follicle centre lymphoma Microchapters |
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary cutaneous follicle centre lymphoma Primary Prevention On the Web |
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma Primary Prevention |
FDA on Primary cutaneous follicle centre lymphoma Primary Prevention |
CDC on Primary cutaneous follicle centre lymphoma Primary Prevention |
Primary cutaneous follicle centre lymphoma Primary Prevention in the news |
Blogs on Primary cutaneous follicle centre lymphoma Primary Prevention |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Risk calculators and risk factors for Primary cutaneous follicle centre lymphoma Primary Prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Soroush Seifirad, M.D.[3]
Overview
There are no established measures for the primary prevention of primary cutaneous follicle centre lymphoma.
OR
There are no available vaccines against primary cutaneous follicle centre lymphoma.
OR
Effective measures for the primary prevention of primary cutaneous follicle centre lymphoma include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent primary cutaneous follicle centre lymphoma. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Primary Prevention
There are no established measures for the primary prevention of primary cutaneous follicle centre lymphoma.
OR
There are no available vaccines against primary cutaneous follicle centre lymphoma.
OR
Effective measures for the primary prevention of primary cutaneous follicle centre lymphoma include:
- [Measure1]
- [Measure2]
- [Measure3]
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent primary cutaneous follicle centre lymphoma. Other primary prevention strategies include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]